From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.

IF 4.1 3区 生物学 Q2 CELL BIOLOGY
Microbial Cell Pub Date : 2024-05-23 eCollection Date: 2024-01-01 DOI:10.15698/mic2024.05.824
Anjali Yadav, Meenakshi Kaushik, Prabhakar Tiwari, Rima Dada
{"title":"From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.","authors":"Anjali Yadav, Meenakshi Kaushik, Prabhakar Tiwari, Rima Dada","doi":"10.15698/mic2024.05.824","DOIUrl":null,"url":null,"abstract":"<p><p>The gut microbiome (GM) has been identified as a crucial factor in the development and progression of various diseases, including cancer. In the case of prostate cancer, commensal bacteria and other microbes are found to be associated with its development. Recent studies have demonstrated that the human GM, including <i>Bacteroides</i>, <i>Streptococcus</i>, <i>Bacteroides massiliensis</i>, <i>Faecalibacterium prausnitzii</i>, <i>Eubacterium rectale</i>, and <i>Mycoplasma genitalium</i>, are involved in prostate cancer development through both direct and indirect interactions. However, the pathogenic mechanisms of these interactions are yet to be fully understood. Moreover, the microbiota influences systemic hormone levels and contributes to prostate cancer pathogenesis. Currently, it has been shown that supplementation of prebiotics or probiotics can modify the composition of GM and prevent the onset of prostate cancer. The microbiota can also affect drug metabolism and toxicity, which may improve the response to cancer treatment. The composition of the microbiome is crucial for therapeutic efficacy and a potential target for modulating treatment response. However, their clinical application is still limited. Additionally, GM-based cancer therapies face limitations due to the complexity and diversity of microbial composition, and the lack of standardized protocols for manipulating gut microbiota, such as optimal probiotic selection, treatment duration, and administration timing, hindering widespread use. Therefore, this review provides a comprehensive exploration of the GM's involvement in prostate cancer pathogenesis. We delve into the underlying mechanisms and discuss their potential implications for both therapeutic and diagnostic approaches in managing prostate cancer. Through this analysis, we offer valuable insights into the pivotal role of the microbiome in prostate cancer and its promising application in future clinical settings.</p>","PeriodicalId":18397,"journal":{"name":"Microbial Cell","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial Cell","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.15698/mic2024.05.824","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The gut microbiome (GM) has been identified as a crucial factor in the development and progression of various diseases, including cancer. In the case of prostate cancer, commensal bacteria and other microbes are found to be associated with its development. Recent studies have demonstrated that the human GM, including Bacteroides, Streptococcus, Bacteroides massiliensis, Faecalibacterium prausnitzii, Eubacterium rectale, and Mycoplasma genitalium, are involved in prostate cancer development through both direct and indirect interactions. However, the pathogenic mechanisms of these interactions are yet to be fully understood. Moreover, the microbiota influences systemic hormone levels and contributes to prostate cancer pathogenesis. Currently, it has been shown that supplementation of prebiotics or probiotics can modify the composition of GM and prevent the onset of prostate cancer. The microbiota can also affect drug metabolism and toxicity, which may improve the response to cancer treatment. The composition of the microbiome is crucial for therapeutic efficacy and a potential target for modulating treatment response. However, their clinical application is still limited. Additionally, GM-based cancer therapies face limitations due to the complexity and diversity of microbial composition, and the lack of standardized protocols for manipulating gut microbiota, such as optimal probiotic selection, treatment duration, and administration timing, hindering widespread use. Therefore, this review provides a comprehensive exploration of the GM's involvement in prostate cancer pathogenesis. We delve into the underlying mechanisms and discuss their potential implications for both therapeutic and diagnostic approaches in managing prostate cancer. Through this analysis, we offer valuable insights into the pivotal role of the microbiome in prostate cancer and its promising application in future clinical settings.

从微生物到药物:利用肠道微生物群防治前列腺癌。
肠道微生物组(GM)已被确定为包括癌症在内的各种疾病发生和发展的关键因素。就前列腺癌而言,共生细菌和其他微生物被发现与癌症的发展有关。最近的研究表明,人类基因组中的乳酸杆菌、链球菌、大肠杆菌、普氏粪杆菌、直肠大肠杆菌和生殖支原体等通过直接或间接的相互作用参与了前列腺癌的发展。然而,这些相互作用的致病机制尚不完全清楚。此外,微生物群还会影响全身激素水平,并导致前列腺癌的发病。目前,已有研究表明,补充益生菌或益生菌可以改变 GM 的组成,预防前列腺癌的发生。微生物群还能影响药物代谢和毒性,从而改善对癌症治疗的反应。微生物组的组成对疗效至关重要,也是调节治疗反应的潜在靶点。然而,其临床应用仍然有限。此外,由于微生物组成的复杂性和多样性,以及缺乏操作肠道微生物群的标准化方案(如最佳益生菌选择、治疗持续时间和给药时机),基于基因改造的癌症疗法面临着种种限制,阻碍了其广泛应用。因此,本综述全面探讨了基因改造在前列腺癌发病机制中的作用。我们深入探讨了其潜在机制,并讨论了它们对前列腺癌治疗和诊断方法的潜在影响。通过分析,我们对微生物组在前列腺癌中的关键作用及其在未来临床中的应用前景提出了宝贵的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Microbial Cell
Microbial Cell Multiple-
CiteScore
6.40
自引率
0.00%
发文量
32
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信